<p>Quadrant Private Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中披露，其在輝瑞公司（NYSE:PFE - 免費報告）的持股在第二季度減少了 10.1%。該公司在季度內出售了 12,001 股後，持有 106,984 股生物製藥公司的股票。截至其最近的 SEC 文件，Quadrant Private Wealth Management LLC 在輝瑞的持股價值為 2,593,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 10/06 - 10/10</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也調整了對該股票的持股。Capital Advisory Group Advisory Services LLC 在第二季度將其在輝瑞的股份增加了 2.9%。Capital Advisory Group Advisory Services LLC 目前持有 13,542 股生物製藥公司的股票，價值 328,000 美元，此前在上個季度增持了 388 股。Citizens National Bank Trust Department 在第二季度將其在輝瑞的持股增加了 0.9%。Citizens National Bank Trust Department 目前持有 46,103 股生物製藥公司的股票，價值 1,118,000 美元，此前在上個季度增持了 395 股。Able Wealth Management LLC 在第二季度將其在輝瑞的持股增加了 2.0%。Able Wealth Management LLC 目前持有 21,128 股生物製藥公司的股票，價值 512,000 美元，此前在上個季度增持了 413 股。Trust Co of the South 在第二季度將其在輝瑞的持股增加了 1.5%。Trust Co of the South 目前持有 29,386 股生物製藥公司的股票，價值 712,000 美元，此前在上個季度增持了 441 股。最後，Charter Oak Capital Management LLC 在第二季度將其在輝瑞的持股增加了 4.3%。Charter Oak Capital Management LLC 目前持有 10,663 股生物製藥公司的股票，價值 258,000 美元，此前在上個季度增持了 444 股。機構投資者持有該公司 68.36% 的股票。</p>
<h2>輝瑞價格表現</h2>
<p>輝瑞（PFE）股票週五開盤價為 24.45 美元。該公司的市值為 1389.9 億美元，市盈率為 13.00，市盈率/增長比率為 0.81，貝塔值為 0.54。該公司的 50 日簡單移動平均線為 24.74 美元，200 日簡單移動平均線為 24.35 美元。輝瑞公司的一年最低價為 20.92 美元，一年最高價為 27.69 美元。該公司的債務與股本比率為 0.65，流動比率為 1.16，速動比率為 0.85。</p>
<ul>
<li>5 個推動醫療行業大反彈的股票</li>
</ul>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 11 月 4 日（星期二）公佈了季度財報。該生物製藥公司報告每股收益（EPS）為 0.87 美元，超出分析師一致預期的 0.79 美元，超出幅度為 0.08 美元。該公司在季度內的收入為 166.5 億美元，而分析師預期為 169.4 億美元。輝瑞的股本回報率為 21.42%，淨利潤率為 16.84%。輝瑞已將 2025 財年的指引設定為 3.000-3.150 EPS。整體來看，股票分析師預計輝瑞公司今年將發佈 2.95 EPS。</p>
<h2>輝瑞宣佈分紅</h2>
<p>該公司最近還披露了季度分紅，將於 12 月 1 日（星期一）支付。11 月 7 日（星期五）登記的投資者將獲得 0.43 美元的分紅。該分紅的除息日為 11 月 7 日（星期五）。這代表着年化分紅為 1.72 美元，收益率為 7.0%。輝瑞的分紅支付比率為 100.00%。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>為什麼 AbbVie 和強生可能會超越輝瑞</li>
</ul>
<p>多家券商最近對 PFE 發表了評論。摩根士丹利將輝瑞的目標價從 33.00 美元下調至 32.00 美元，並在 10 月 10 日（星期五）的研究報告中對該公司給予了 “持平” 評級。高盛集團重申了 “中性” 評級，並在週三對輝瑞的股票設定了 26.00 美元的目標價。Sanford C. Bernstein 在 10 月 31 日（星期五）的報告中重新發布了 “市場表現” 評級，並對輝瑞的股票設定了 30.00 美元的目標價。瑞銀集團在 10 月 1 日（星期三）的研究報告中重申了 “中性” 評級，並對輝瑞的股票設定了 28.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對輝瑞股票的 “持有（c-）” 評級。一位股票研究分析師對該股票給予了強烈買入評級，四位給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 28.18 美元。</p>
<p><strong>查看我們最新的輝瑞股票分析</strong></p>
<h2>輝瑞簡介</h2>
<p>（免費報告）</p>
<p>輝瑞公司在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在滿足醫療需求的傳染病領域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及未來潛在的 mRNA 和抗病毒產品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過輝瑞</li>
<li>如何從成長投資中獲利</li>
<li>OpenAI 的重組為可能成為最大 IPO 鋪平了道路</li>
<li>投資者如何從盤後交易中受益</li>
<li>2 只美國政府不希望失敗的稀土股票</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
<p><strong>想知道其他對 PFE 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

<p>Quadrant Private Wealth Management LLC 在第二季度減少了對輝瑞公司（NYSE:PFE）10.1% 的持股，出售了 12,001 股，剩餘 106,984 股，市值為 2,593,000 美元。其他機構投資者也調整了他們的持股。輝瑞的股票開盤價為 24.45 美元，市值為 1,389.9 億美元。該公司報告第三季度每股收益為 0.87 美元，超出預期，並宣佈季度股息為 0.43 美元，收益率為 7.0%。分析師對輝瑞的評級不一，目標價格範圍在 26.00 美元到 33.00 美元之間</p>

<p>Quadrant Private Wealth Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 10.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,984 shares of the biopharmaceutical company's stock after selling 12,001 shares during the quarter. Quadrant Private Wealth Management LLC's holdings in Pfizer were worth $2,593,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Quadrant Private Wealth Management LLC 在最近向證券交易委員會（SEC）提交的文件中披露，其在輝瑞公司（NYSE:PFE - 免費報告）的持股在第二季度減少了 10.1%。該公司在季度內出售了 12,001 股後，持有 106,984 股生物製藥公司的股票。截至其最近的 SEC 文件，Quadrant Private Wealth Management LLC 在輝瑞的持股價值為 2,593,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/06 - 10/10</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 10/06 - 10/10</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares during the last quarter. Able Wealth Management LLC grew its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Trust Co of the South grew its position in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Finally, Charter Oak Capital Management LLC increased its holdings in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the last quarter. Institutional investors own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也調整了對該股票的持股。Capital Advisory Group Advisory Services LLC 在第二季度將其在輝瑞的股份增加了 2.9%。Capital Advisory Group Advisory Services LLC 目前持有 13,542 股生物製藥公司的股票，價值 328,000 美元，此前在上個季度增持了 388 股。Citizens National Bank Trust Department 在第二季度將其在輝瑞的持股增加了 0.9%。Citizens National Bank Trust Department 目前持有 46,103 股生物製藥公司的股票，價值 1,118,000 美元，此前在上個季度增持了 395 股。Able Wealth Management LLC 在第二季度將其在輝瑞的持股增加了 2.0%。Able Wealth Management LLC 目前持有 21,128 股生物製藥公司的股票，價值 512,000 美元，此前在上個季度增持了 413 股。Trust Co of the South 在第二季度將其在輝瑞的持股增加了 1.5%。Trust Co of the South 目前持有 29,386 股生物製藥公司的股票，價值 712,000 美元，此前在上個季度增持了 441 股。最後，Charter Oak Capital Management LLC 在第二季度將其在輝瑞的持股增加了 4.3%。Charter Oak Capital Management LLC 目前持有 10,663 股生物製藥公司的股票，價值 258,000 美元，此前在上個季度增持了 444 股。機構投資者持有該公司 68.36% 的股票。</p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>輝瑞價格表現</h2>
</div><p>Shares of PFE stock opened at $24.45 on Friday. The company has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. The company's 50-day simple moving average is $24.74 and its two-hundred day simple moving average is $24.35. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.</p>
<div class="lb-trans"><p>輝瑞（PFE）股票週五開盤價為 24.45 美元。該公司的市值為 1389.9 億美元，市盈率為 13.00，市盈率/增長比率為 0.81，貝塔值為 0.54。該公司的 50 日簡單移動平均線為 24.74 美元，200 日簡單移動平均線為 24.35 美元。輝瑞公司的一年最低價為 20.92 美元，一年最高價為 27.69 美元。該公司的債務與股本比率為 0.65，流動比率為 1.16，速動比率為 0.85。</p>
</div><ul>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>5 個推動醫療行業大反彈的股票</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 11 月 4 日（星期二）公佈了季度財報。該生物製藥公司報告每股收益（EPS）為 0.87 美元，超出分析師一致預期的 0.79 美元，超出幅度為 0.08 美元。該公司在季度內的收入為 166.5 億美元，而分析師預期為 169.4 億美元。輝瑞的股本回報率為 21.42%，淨利潤率為 16.84%。輝瑞已將 2025 財年的指引設定為 3.000-3.150 EPS。整體來看，股票分析師預計輝瑞公司今年將發佈 2.95 EPS。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>輝瑞宣佈分紅</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio is 100.00%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，將於 12 月 1 日（星期一）支付。11 月 7 日（星期五）登記的投資者將獲得 0.43 美元的分紅。該分紅的除息日為 11 月 7 日（星期五）。這代表着年化分紅為 1.72 美元，收益率為 7.0%。輝瑞的分紅支付比率為 100.00%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 AbbVie 和強生可能會超越輝瑞</li>
</ul>
</div><p>A number of brokerages recently commented on PFE. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday, October 10th. The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday. Sanford C. Bernstein reissued a &#34;market perform&#34; rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. UBS Group restated a &#34;neutral&#34; rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of Pfizer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $28.18.</p>
<div class="lb-trans"><p>多家券商最近對 PFE 發表了評論。摩根士丹利將輝瑞的目標價從 33.00 美元下調至 32.00 美元，並在 10 月 10 日（星期五）的研究報告中對該公司給予了 “持平” 評級。高盛集團重申了 “中性” 評級，並在週三對輝瑞的股票設定了 26.00 美元的目標價。Sanford C. Bernstein 在 10 月 31 日（星期五）的報告中重新發布了 “市場表現” 評級，並對輝瑞的股票設定了 30.00 美元的目標價。瑞銀集團在 10 月 1 日（星期三）的研究報告中重申了 “中性” 評級，並對輝瑞的股票設定了 28.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對輝瑞股票的 “持有（c-）” 評級。一位股票研究分析師對該股票給予了強烈買入評級，四位給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，共識目標價為 28.18 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的輝瑞股票分析</strong></p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>輝瑞簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>輝瑞公司在美國、歐洲及國際上發現、開發、製造、營銷、分銷和銷售生物製藥產品。該公司在多個治療領域提供藥物和疫苗，包括心血管代謝、偏頭痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在滿足醫療需求的傳染病領域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的預防和治療，以及未來潛在的 mRNA 和抗病毒產品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How to Profit From Growth Investing</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過輝瑞</li>
<li>如何從成長投資中獲利</li>
<li>OpenAI 的重組為可能成為最大 IPO 鋪平了道路</li>
<li>投資者如何從盤後交易中受益</li>
<li>2 只美國政府不希望失敗的稀土股票</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 PFE 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Quadrant Private Wealth Management LLC Sells 12,001 Shares of Pfizer Inc. $PFE

- Quadrant Private Wealth Management LLC 在第二季度減持了 10.1% 的 Pfizer 持股。  
- 該公司目前持有 106,984 股，市值約為 2,593,000 美元。  
- Pfizer 最近公佈的季度每股收益為 0.87 美元，超出預期。  

Quadrant 私人財富管理有限責任公司出售了輝瑞公司 12,001 股股票